Clinical Trials Logo
  1. Home
  2. Lung Cancer
  3. NCT03250390
  4. Details
NCT03250390 Clinical Trial

Breath Analysis to Diagnose Lung Cancer

Lung Cancer Clinical Trial

— CATOCOV  

Official title:
Analysis of Volatile Organic Compounds in Exhaled Air as a Diagnostic Tool for Thoracic Cancers

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03250390
Other study ID # 2017_05
Secondary ID 2017-A00932-51PH
Status Recruiting
Phase N/A
First received
Last updated
Start date April 29, 2019
Est. completion date April 29, 2023

Study information
Verified date October 2022
Source University Hospital, Lille
Contact Sébastien Hulo, MD
Phone 3.20.44.52.85
Email sebastien.hulo@chru-lille.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determination of volatile organic compounds to discriminate patients with lung cancer from healthy smokers and non-smokers healthy subjects.

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date April 29, 2023
Est. primary completion date April 29, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patients with histologically proven lung cancer Controls: - healthy smoker or non-smoker subjects - without respiratory diseases excepted chronic obstructive pulmonary disease. Exclusion Criteria: - history of cancer other than lung cancer within 5 years before inclusion - oral or facial malformation - incomprehension of maneuvers for the collection

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Collection of volatile organic compounds during exhalation
The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler. The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)

Locations
Country Name City State
France Hôpital Calmette, CHU Lille
France Institut Pasteur - Centre de Prévention et d'Education à la Santé (CPES) Lille
France Hopital Victor Provo Roubaix
France Centre Hospitalier de Saint Quentin Saint-Quentin
France Chu Amiens Salouël Salouël
France Ch Seclin - Seclin Seclin
France Clinique Teissier Valenciennes

Sponsors (4)
Lead Sponsor Collaborator
University Hospital, Lille Institut MinesTelecom (IMT), Institut National de Recherche en Informatique et en Automatique, Institut Pasteur de Lille

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Discriminating power of VOCs Discriminating power of VOCs using discriminant analyzes using innovative data mining methods based on multi-objective combinatorial optimization. 34 months
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk